16-Mar-2026
No headlines found.
Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD
Business Wire (Tue, 3-Mar 7:55 AM ET)
Newsfile (Wed, 11-Feb 4:22 PM ET)
Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations
Business Wire (Mon, 9-Feb 6:45 PM ET)
Newsfile (Mon, 9-Feb 4:34 PM ET)
PRNewswire (Sun, 8-Feb 12:51 PM ET)
Newsfile (Fri, 6-Feb 9:55 PM ET)
Simulations Plus to Participate in Upcoming Investor Conferences
Business Wire (Tue, 3-Feb 4:05 PM ET)
Newsfile (Sun, 1-Feb 10:25 AM ET)
Newsfile (Sat, 31-Jan 9:09 AM ET)
Newsfile (Mon, 26-Jan 4:52 PM ET)
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Simulations Plus trades on the NASDAQ stock market under the symbol SLP.
As of March 16, 2026, SLP stock price declined to $12.12 with 257,761 million shares trading.
SLP has a beta of 1.02, meaning it tends to be more sensitive to market movements. SLP has a correlation of 0.05 to the broad based SPY ETF.
SLP has a market cap of $243.94 million. This is considered a Small Cap stock.
Last quarter Simulations Plus reported $18 million in Revenue and $.17 earnings per share. This beat revenue expectation by $334,800 and missed earnings estimates by -$.02.
In the last 3 years, SLP traded as high as $52.69 and as low as $11.16.
The top ETF exchange traded funds that SLP belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
SLP has underperformed the market in the last year with a return of -52.2%, while the SPY ETF gained +22.6%. In the last 3 month period, SLP fell short of the market, returning -36.8%, while SPY returned -1.6%. However, in the most recent 2 weeks SLP has outperformed the stock market by returning -0.9%, while SPY returned -2.5%.
SLP support price is $12.04 and resistance is $12.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLP shares will trade within this expected range on the day.
